Introduction
Intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) agents have become the gold standard for treating various retinal vascular diseases, including neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO). While these therapies are highly effective in preserving and improving visual acuity, their long-term safety profile regarding the anterior segment remains a subject of investigation. This report analyzes the clinical impact of chronic anti-VEGF administration on the development and progression of cataracts leading to surgical intervention.
